DiscoverRopesTalkNon-binding Guidance: The Administration’s Focus on Direct-to-Consumer Prescription Drug Advertising
Non-binding Guidance: The Administration’s Focus on Direct-to-Consumer Prescription Drug Advertising

Non-binding Guidance: The Administration’s Focus on Direct-to-Consumer Prescription Drug Advertising

Update: 2025-10-06
Share

Description

In this episode of Non-binding Guidance, Greg Levine and Josh Oyster, partners in Ropes & Gray’s life sciences regulatory and compliance practice group, are joined by Kellie Combs, partner and chair of Ropes & Gray’s life sciences regulatory and compliance practice group, to discuss the Trump administration’s recent crackdown on direct-to-consumer (DTC) prescription drug advertising. The conversation explores the coordinated actions by HHS and FDA, aggressive enforcement measures, proposed rulemaking to reshape DTC broadcast ads, and the use of AI in regulatory oversight. The hosts examine the impact of recent FDA enforcement letters, challenges in digital and social media promotion, and the shifting compliance landscape for pharmaceutical companies. This episode offers practical guidance for life sciences companies navigating this rapidly changing regulatory environment.

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Non-binding Guidance: The Administration’s Focus on Direct-to-Consumer Prescription Drug Advertising

Non-binding Guidance: The Administration’s Focus on Direct-to-Consumer Prescription Drug Advertising

Ropes & Gray LLP